세계의 종양학 바이오시밀러 시장

The global market for oncology biosimilars is estimated to grow from $9.6 billion in 2025 and projected to reach $17.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2030.

The North American market for oncology biosimilars is estimated to grow from $3.1 billion in 2025 and projected to reach $5.7 billion by the end of 2030, at a CAGR of 13.4% from 2025 to 2030.

The Asia-Pacific market for oncology biosimilars is estimated to grow from $2.5 billion in 2025 and projected to reach $4.8 billion by the end of 2030, at a CAGR of 14.1% from 2025 to 2030.

Report Scope

The report examines and segments the global oncology biosimilars market by indication, drug class, route of administration and distribution channel. It also provides insights into key emerging trends and potential growth drivers. The study focuses on indications such as breast, lung and blood cancers and others. By drug class, it focuses on granulocyte colony-stimulating factors, monoclonal antibodies, hematopoietic agents and others. By route of administration, the focus is on intravenous, subcutaneous and others. The report also examines hospital, retail and online pharmacies and others by distribution channel.

Included is a regional analysis of North America, Europe, Asia-Pacific, South America and the Middle East and Africa that evaluates the impact of AI adoption on the oncology biosimilars industry and market dynamics, including drivers, challenges and emerging trends, while highlighting product and performance enhancement innovations. The study concludes with an analysis of major companies in the market and their offerings.

It includes global revenue ($ million) for the base year 2024, estimated for 2025 and data for the forecast period 2026 through 2030.

Report Includes

• 140 data tables and 40 additional tables
• In-depth analysis of the global market for oncology biosimilar drugs
• Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by disease indication (cancer type), drug class, route of administration, distribution channel and region
• Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
• Impact analysis of the U.S. tariffs on the market for biologics used in cancer treatment and supportive care
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• A relevant patent analysis, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Samsung Bioepis, Sandoz Group AG, Celltrion Inc., Amgen Inc., and Biocon Biologics Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Current Market Overview
• Future Outlook
• Analysis of Macroeconomic Factors
• Impact of U.S. Tariffs on the Market
• Impact of the Ukraine-Russia War
• Economic Growth and Development
• Demographic Shifts
• Healthcare Expenditure Trends
• Inflation and Currency Fluctuations
• Porter's Five Forces Analysis

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Surge in Global Cancer Incidence
• Expiration of Blockbuster Biologic Patents
• Need for Cost-Effective Cancer Therapies
• Demand for Targeted and Supportive Oncology Treatments
• Market Restraints
• Regulatory Complexity and Approval Hurdles
• Patent Challenges and Legal Barriers
• Pharmacy Benefit Manager Practices
• Market Opportunities
• Expansion into Emerging Markets
• Development of Novel Biosimilar Combinations and Specialty Formulations

Chapter 4 Regulatory Landscape

• Regulatory Framework
• U.S.
• Europe
• India
• Australia
• Japan

Chapter 5 Emerging Technologies and New Developments

• Overview
• Emerging Technologies
• Advanced Cell Line Engineering
• Artificial Intelligence and Machine Learning in Biosimilar Development
• Gene Editing and Synthetic Biology Approaches
• Modular and Single-Use Bioreactors
• Patent Analysis
• Key Takeaways
• Patents, by Year
• Patents, by Leading Jurisdiction
• Patents, by Leading Inventor

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Oncology Biosimilars Market, by Indication
• Key Takeaways
• Breast Cancer
• Lung Cancer
• Blood Cancer
• Others
• Global Oncology Biosimilars Market, by Drug Class
• Key Takeaways
• Granulocyte Colony-Stimulating Factor
• Monoclonal Antibodies
• Hematopoietic Agents
• Others
• Global Oncology Biosimilars Market, by Route of Administration
• Key Takeaways
• Intravenous
• Subcutaneous
• Others RoA
• Global Oncology Biosimilars Market, by Distribution Channel
• Key Takeaways
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
• Geographic Breakdown
• Global Oncology Biosimilars Market, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Industry Structure
• Company Share Analysis for Oncology Biosimilars Market
• Strategic Analysis

Chapter 8 Sustainability in the Oncology Biosimilars Market: ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives of the Oncology Biosimilars Industry
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Abbreviations
• Company Profiles
• ACCORD HEALTHCARE
• ALVOTECH
• AMGEN INC.
• AMNEAL PHARMACEUTICALS LLC.
• APOTEX INC.
• BIOCAD
• BIOCON BIOLOGICS LTD.
• CELLTRION INC.
• FRESENIUS KABI AG
• PFIZER INC.
• SAMSUNG BIOEPIS
• SANDOZ GROUP AG
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC.
• Emerging Start-ups/Market Disruptors